Sinocare Inc
Sinocare Inc. engages in the development, manufacture, and marketing of rapid diagnosis testing products primarily in the People's Republic of China. It offers blood glucose and pressure monitors; point of care testing products; digital management tool solutions; non-invasive screening products; and PTS and Trividia products. The company provides its products for the patients with chronic disease… Read more
Sinocare Inc (300298) - Net Assets
Latest net assets as of September 2025: CN¥3.67 Billion CNY
Based on the latest financial reports, Sinocare Inc (300298) has net assets worth CN¥3.67 Billion CNY as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥6.25 Billion) and total liabilities (CN¥2.57 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥3.67 Billion |
| % of Total Assets | 58.81% |
| Annual Growth Rate | 39.94% |
| 5-Year Change | 37.52% |
| 10-Year Change | 203.97% |
| Growth Volatility | 92.89 |
Sinocare Inc - Net Assets Trend (2008–2024)
This chart illustrates how Sinocare Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Sinocare Inc (2008–2024)
The table below shows the annual net assets of Sinocare Inc from 2008 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥3.77 Billion | +8.61% |
| 2023-12-31 | CN¥3.47 Billion | +10.41% |
| 2022-12-31 | CN¥3.14 Billion | +12.58% |
| 2021-12-31 | CN¥2.79 Billion | +1.87% |
| 2020-12-31 | CN¥2.74 Billion | +3.48% |
| 2019-12-31 | CN¥2.65 Billion | +0.99% |
| 2018-12-31 | CN¥2.62 Billion | +88.76% |
| 2017-12-31 | CN¥1.39 Billion | +8.75% |
| 2016-12-31 | CN¥1.28 Billion | +3.04% |
| 2015-12-31 | CN¥1.24 Billion | +11.59% |
| 2014-12-31 | CN¥1.11 Billion | +17.47% |
| 2013-12-31 | CN¥946.01 Million | +11.93% |
| 2012-12-31 | CN¥845.18 Million | +370.82% |
| 2011-12-31 | CN¥179.51 Million | +96.51% |
| 2010-12-31 | CN¥91.35 Million | +120.16% |
| 2009-12-31 | CN¥41.49 Million | +138.21% |
| 2008-12-31 | CN¥17.42 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Sinocare Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 10570.3% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥1.13 Billion | 33.56% |
| Common Stock | CN¥564.27 Million | 16.80% |
| Other Components | CN¥1.67 Billion | 49.63% |
| Total Equity | CN¥3.36 Billion | 100.00% |
Sinocare Inc Competitors by Market Cap
The table below lists competitors of Sinocare Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Standard Lithium Ltd
NYSE MKT:SLI
|
$952.68 Million |
|
Arcos Dorados Holdings Inc
NYSE:ARCO
|
$952.86 Million |
|
Kent Gida Maddeleri Sanayi ve Ticaret AS
IS:KENT
|
$953.15 Million |
|
Montnets Cloud Technology Group Co Ltd
SHE:002123
|
$953.24 Million |
|
Shoals Technologies Group Inc
NASDAQ:SHLS
|
$952.43 Million |
|
ChemoMetec A/S
CO:CHEMM
|
$951.64 Million |
|
VIMEO INC. DL-01
F:4KS
|
$951.29 Million |
|
Jiangsu Lihua Animal Husbandry Co Ltd
SHE:300761
|
$950.98 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Sinocare Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 3,078,648,376 to 3,357,739,858, a change of 279,091,482 (9.1%).
- Net income of 326,291,000 contributed positively to equity growth.
- Dividend payments of 132,189,521 reduced retained earnings.
- Share repurchases of 50,805,313 reduced equity.
- Other factors increased equity by 135,795,316.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥326.29 Million | +9.72% |
| Dividends Paid | CN¥132.19 Million | -3.94% |
| Share Repurchases | CN¥50.81 Million | -1.51% |
| Other Changes | CN¥135.80 Million | +4.04% |
| Total Change | CN¥- | 9.07% |
Book Value vs Market Value Analysis
This analysis compares Sinocare Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.77x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 319.56x to 2.77x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2008-12-31 | CN¥0.05 | CN¥16.78 | x |
| 2009-12-31 | CN¥0.13 | CN¥16.78 | x |
| 2010-12-31 | CN¥0.28 | CN¥16.78 | x |
| 2011-12-31 | CN¥0.50 | CN¥16.78 | x |
| 2012-12-31 | CN¥2.81 | CN¥16.78 | x |
| 2013-12-31 | CN¥1.95 | CN¥16.78 | x |
| 2014-12-31 | CN¥2.96 | CN¥16.78 | x |
| 2015-12-31 | CN¥3.29 | CN¥16.78 | x |
| 2016-12-31 | CN¥2.62 | CN¥16.78 | x |
| 2017-12-31 | CN¥2.85 | CN¥16.78 | x |
| 2018-12-31 | CN¥4.70 | CN¥16.78 | x |
| 2019-12-31 | CN¥4.75 | CN¥16.78 | x |
| 2020-12-31 | CN¥4.90 | CN¥16.78 | x |
| 2021-12-31 | CN¥4.96 | CN¥16.78 | x |
| 2022-12-31 | CN¥5.59 | CN¥16.78 | x |
| 2023-12-31 | CN¥5.53 | CN¥16.78 | x |
| 2024-12-31 | CN¥6.06 | CN¥16.78 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Sinocare Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 9.72%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 7.34%
- • Asset Turnover: 0.73x
- • Equity Multiplier: 1.82x
- Recent ROE (9.72%) is below the historical average (21.65%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2008 | 41.15% | 20.30% | 1.20x | 1.68x | CN¥5.43 Million |
| 2009 | 62.84% | 37.50% | 0.98x | 1.72x | CN¥21.92 Million |
| 2010 | 60.05% | 34.24% | 1.09x | 1.60x | CN¥45.72 Million |
| 2011 | 49.11% | 42.09% | 0.87x | 1.34x | CN¥70.21 Million |
| 2012 | 15.24% | 37.99% | 0.36x | 1.12x | CN¥44.31 Million |
| 2013 | 17.47% | 36.81% | 0.43x | 1.11x | CN¥70.71 Million |
| 2014 | 17.76% | 36.21% | 0.45x | 1.09x | CN¥86.21 Million |
| 2015 | 11.62% | 22.26% | 0.48x | 1.08x | CN¥19.98 Million |
| 2016 | 9.03% | 14.48% | 0.54x | 1.16x | CN¥-12.32 Million |
| 2017 | 18.56% | 24.97% | 0.62x | 1.20x | CN¥119.01 Million |
| 2018 | 11.84% | 20.02% | 0.52x | 1.14x | CN¥48.15 Million |
| 2019 | 9.46% | 14.10% | 0.54x | 1.24x | CN¥-14.21 Million |
| 2020 | 6.84% | 9.27% | 0.52x | 1.43x | CN¥-86.49 Million |
| 2021 | 3.86% | 4.56% | 0.57x | 1.49x | CN¥-171.00 Million |
| 2022 | 14.30% | 11.30% | 0.86x | 1.48x | CN¥134.33 Million |
| 2023 | 9.24% | 7.01% | 0.68x | 1.93x | CN¥-23.47 Million |
| 2024 | 9.72% | 7.34% | 0.73x | 1.82x | CN¥-9.48 Million |
Industry Comparison
This section compares Sinocare Inc's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $2,086,657,284
- Average return on equity (ROE) among peers: 22.84%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Sinocare Inc (300298) | CN¥3.67 Billion | 41.15% | 0.70x | $952.60 Million |
| Shanghai Kehua Bio-Engineering Co Ltd (002022) | $792.82 Million | 25.77% | 0.17x | $318.98 Million |
| Jiangsu Yuyue Medical Equipment & Supply Co Ltd (002223) | $482.51 Million | 20.84% | 0.32x | $2.79 Billion |
| Double Medical Technology Inc (002901) | $224.61 Million | 43.10% | 0.32x | $404.40 Million |
| Wuhan Easy Diagnosis Biomedicine Co Ltd Class A (002932) | $1.42 Million | 98.49% | 2.27x | $281.14 Million |
| Lepu Medical Tech Beijing (300003) | $12.27 Billion | 14.01% | 0.69x | $2.71 Billion |
| INKON Life Technology Co Ltd (300143) | $1.81 Billion | -20.17% | 0.37x | $637.77 Million |
| Edan Instruments Inc (300206) | $1.26 Billion | 7.37% | 0.15x | $501.55 Million |
| Guangdong Biolight Meditech Co Ltd (300246) | $504.27 Million | 13.31% | 0.36x | $360.97 Million |
| Beijing Leadman Biochemistry Co Ltd (300289) | $1.44 Billion | 2.82% | 0.20x | $267.10 Million |